Genprex Announces Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 Diabetes

Core Viewpoint - Genprex, Inc. plans to create a new subsidiary focused on diabetes gene therapy, GPX-002, while retaining its oncology programs, aiming to enhance focus and attract investment in both areas [1][2][3]. Company Strategy - The separation of the diabetes program into a new subsidiary, NewCo, is intended to increase interest and expedite clinical development for GPX-002, a gene therapy for Type 1 and Type 2 diabetes [2][3]. - Genprex aims to streamline its oncology clinical development program alongside the diabetes initiative, demonstrating a commitment to focused strategies and research prioritization [3]. Product Development - GPX-002 is designed to transform pancreatic alpha cells into functional beta-like cells to produce insulin, with preclinical studies showing promising results in restoring normal blood glucose levels [4][6]. - The gene therapy approach for Type 2 diabetes involves rejuvenating exhausted beta cells, with the potential to disrupt traditional diabetes treatments [5][8]. Market Context - As of 2024, approximately 38.4 million Americans have diabetes, with projections indicating a rise to 643 million globally by 2030 [9]. - The diabetes market has seen significant health expenditures, totaling approximately $966 billion in 2021, reflecting a 316% increase over the past 15 years [9]. Research and Collaboration - Preclinical data presented at the ATTD 2023 conference highlighted GPX-002's therapeutic potential, showing decreased insulin requirements and improved glucose tolerance in animal models [7]. - Genprex collaborates with the University of Pittsburgh for the development of GPX-002, leveraging academic research to optimize its clinical candidates [4][10].